Luciana Martins de Carvalho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Luciana Martins de Carvalho has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
- Clovis Artur Silva
Instituto da Criança e do Adolescente, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil
6 shared publications - Virginia Paes Leme Ferriani
Division of Pediatric Rheumatology, Department of Pediatrics, Ribeirão Preto Medical School University of São Paulo Ribeirão Preto Brazil
5 shared publications - Eloisa Bonfá
Rheumatology Division, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil
4 shared publications - Flavio Roberto Sztajnbok
Rheumatology Division, Instituto de Puericultura e Pediatria Martagão Gesteira Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil
4 shared publications - Nadia Emi Aikawa
Instituto da Criança e do Adolescente, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil; Division of Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil
4 shared publications - Rosa Maria Rodrigues Pereira
Department of Medicine, Rheumatology Division, Hospital das Clinicas HCFMUSP Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
4 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 83 (3) , 412-421
Abdominal pain in pediatric immunoglobulin A vasculitis: Risk factors and severity predictors in a multicenter cohort
Objectives: To identify risk factors for abdominal pain and predictors of complicated abdominal pain in pediatric immunoglobulin A vasculitis (IgAV). Methods: Retrospective multicenter study including children and adolescents (≤18 years) fulfilling the European League Against Rheumatism/Pediatric Rheumatology International Trials Organization/Pediatric Rheumatology European Society (EULAR/PRINTO/PRES) criteria for IgAV and followed at four tertiary centers in Brazil. Factors associated with abdominal pain in the overall cohort and with complicated abdominal pain (defined as abdominal pain associated with intussusception, intestinal bleeding, or acute abdomen) were evaluated during the first 3 months of the disease and at the end of follow‐up. Univariate analyses, a pre‐specified multivariable log‐binomial regression model, and receiver operating characteristic (ROC) curve analysis were performed. Results: Among the 687 pediatric patients with IgAV, 420 (61.1%) developed abdominal pain within the first 3 months and 428 (62.3%) by the end of follow‐up (median follow‐up of 54.1 months [interquartile range 50.7–59.3]). Among patients with abdominal pain, 22.2% developed complications. Prolonged purpuric/petechial rash (>29 days; RRadj 1.78, 95% confidence interval [CI] 1.09–2.91) and leukocytosis (>13,500/mm 3 ; RRadj 2.30, 95% CI 1.41–3.73) were independently associated with complications. Leukocytosis showed good discriminatory performance for predicting acute abdomen (area under the curve 0.813, 95% CI 0.704–0.923). Conclusion: Prolonged purpuric/petechial rash and leukocytosis were independently associated with complicated abdominal pain. Leukocytosis may help identify children at higher risk of acute abdomen.
- 1 July 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 83 (3) , 412-421
Open AccessAbdominal pain in pediatric immunoglobulin A vasculitis: Risk factors and severity predictors in a multicenter cohort
Objectives: To identify risk factors for abdominal pain and predictors of complicated abdominal pain in pediatric immunoglobulin A vasculitis (IgAV). Methods: Retrospective multicenter study including children and adolescents (≤18 years) fulfilling the European League Against Rheumatism/Pediatric Rheumatology International Trials Organization/Pediatric Rheumatology European Society (EULAR/PRINTO/PRES) criteria for IgAV and followed at four tertiary centers in Brazil. Factors associated with abdominal pain in the overall cohort and with complicated abdominal pain (defined as abdominal pain associated with intussusception, intestinal bleeding, or acute abdomen) were evaluated during the first 3 months of the disease and at the end of follow‐up. Univariate analyses, a pre‐specified multivariable log‐binomial regression model, and receiver operating characteristic (ROC) curve analysis were performed. Results: Among the 687 pediatric patients with IgAV, 420 (61.1%) developed abdominal pain within the first 3 months and 428 (62.3%) by the end of follow‐up (median follow‐up of 54.1 months [interquartile range 50.7–59.3]). Among patients with abdominal pain, 22.2% developed complications. Prolonged purpuric/petechial rash (>29 days; RRadj 1.78, 95% confidence interval [CI] 1.09–2.91) and leukocytosis (>13,500/mm 3 ; RRadj 2.30, 95% CI 1.41–3.73) were independently associated with complications. Leukocytosis showed good discriminatory performance for predicting acute abdomen (area under the curve 0.813, 95% CI 0.704–0.923). Conclusion: Prolonged purpuric/petechial rash and leukocytosis were independently associated with complicated abdominal pain. Leukocytosis may help identify children at higher risk of acute abdomen.
- Open Access
- 16 April 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Validation of a semi-quantitative ultrasonography score for knee synovitis in juvenile idiopathic arthritis and its association with clinical findings
- 16 April 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Open AccessValidation of a semi-quantitative ultrasonography score for knee synovitis in juvenile idiopathic arthritis and its association with clinical findings
- Open Access
- 13 December 2025
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
AFG2B gene variants and elevated protein expression in lupus nephritis: new insights into childhood-onset systemic lupus erythematosus
Background: Previous genome-wide association studies (GWAS) have associated chronic kidney disease with AFG2B variants. The AFG2B protein is linked to key immune-regulating processes through its interaction with proteasome proteins implicated in systemic inflammation. Dysregulation of these processes is a key factor in the onset of childhood-onset systemic lupus erythematosus (cSLE). This study aimed to investigate the frequency of AFG2B gene variants and the renal expression of the AFG2B protein in cSLE. Methods: This two-phase, cross-sectional observational study included 45 patients with cSLE from a tertiary hospital in Brazil. In the first phase, we determined the frequency of variants in the AFG2B gene using PCR followed by Sanger sequencing. In the second phase, we analyzed AFG2B protein expression via immunohistochemistry in renal biopsies from patients with lupus nephritis (LN) and analyzed two publicly available databases from the Gene Expression Omnibus (GEO)—GSE32591 and GSE127797. To compare AFG2B expression in the LN, we used renal biopsy samples from patients undergoing nephrectomy for non-renal diseases (disease-free controls). We also performed modeling and molecular dynamics of AFG2B protein variants with pathogenic potential. Results: One patient with cSLE (2.2%) had a missense variant in exon 5 of the AFG2B gene (c.1774 A > G); molecular dynamics studies indicated this variant (p.N592D) is more stable than the wild-type protein. Twenty-five patients (55.5%) had an intronic variant (g.12211 A > G), and one patient (2.2%) had a novel intronic variant in heterozygosity (g.13196 A > G). Kidney tissue samples from patients with cSLE exhibited significantly increased AFG2B protein expression compared to normal kidney tissues ( p < 0.01). We also observed a positive correlation between AFG2B protein expression in the tubules and the urinary protein-to-creatinine ratio (UPCR) in patients with cSLE. Conclusions: AFG2B protein expression is significantly elevated in the renal tissues of patients with LN compared to that in controls. Furthermore, its expression in renal tubules correlated positively with the UPCR. These results suggest a potential role for this gene in the pathophysiology of cSLE and warrant further functional investigation.
- 13 December 2025
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Open AccessAFG2B gene variants and elevated protein expression in lupus nephritis: new insights into childhood-onset systemic lupus erythematosus
Background: Previous genome-wide association studies (GWAS) have associated chronic kidney disease with AFG2B variants. The AFG2B protein is linked to key immune-regulating processes through its interaction with proteasome proteins implicated in systemic inflammation. Dysregulation of these processes is a key factor in the onset of childhood-onset systemic lupus erythematosus (cSLE). This study aimed to investigate the frequency of AFG2B gene variants and the renal expression of the AFG2B protein in cSLE. Methods: This two-phase, cross-sectional observational study included 45 patients with cSLE from a tertiary hospital in Brazil. In the first phase, we determined the frequency of variants in the AFG2B gene using PCR followed by Sanger sequencing. In the second phase, we analyzed AFG2B protein expression via immunohistochemistry in renal biopsies from patients with lupus nephritis (LN) and analyzed two publicly available databases from the Gene Expression Omnibus (GEO)—GSE32591 and GSE127797. To compare AFG2B expression in the LN, we used renal biopsy samples from patients undergoing nephrectomy for non-renal diseases (disease-free controls). We also performed modeling and molecular dynamics of AFG2B protein variants with pathogenic potential. Results: One patient with cSLE (2.2%) had a missense variant in exon 5 of the AFG2B gene (c.1774 A > G); molecular dynamics studies indicated this variant (p.N592D) is more stable than the wild-type protein. Twenty-five patients (55.5%) had an intronic variant (g.12211 A > G), and one patient (2.2%) had a novel intronic variant in heterozygosity (g.13196 A > G). Kidney tissue samples from patients with cSLE exhibited significantly increased AFG2B protein expression compared to normal kidney tissues ( p < 0.01). We also observed a positive correlation between AFG2B protein expression in the tubules and the urinary protein-to-creatinine ratio (UPCR) in patients with cSLE. Conclusions: AFG2B protein expression is significantly elevated in the renal tissues of patients with LN compared to that in controls. Furthermore, its expression in renal tubules correlated positively with the UPCR. These results suggest a potential role for this gene in the pathophysiology of cSLE and warrant further functional investigation.
- Open Access
- 6 February 2024
- Published by Springer Nature in Advances in Rheumatology
- Vol. 64 (1) , 1-7
Childhood-onset systemic lupus erythematosus (cSLE) and malignancy: a nationwide multicentre series review
Background: Increased malignancy frequency is well documented in adult-systemic lupus erythematosus (SLE), but with limited reports in childhood-onset SLE (cSLE) series. We explored the frequency of malignancy associated with cSLE, describing clinical and demographic characteristics, disease activity and cumulative damage, by the time of malignancy diagnosis. Method: A retrospective case-notes review, in a nationwide cohort from 27 Pediatric Rheumatology centres, with descriptive biopsy-proven malignancy, disease activity/damage accrual, and immunosuppressive treatment were compiled in each participating centre, using a standard protocol. Results: Of the 1757 cSLE cases in the updated cohort, 12 (0.7%) developed malignancy with median time 10 years after cSLE diagnosis. There were 91% females, median age at cSLE diagnosis 12 years, median age at malignancy diagnosis 23 years. Of all diagnosed malignancies, 11 were single-site, and a single case with concomitant multiple sites; four had haematological (0.22%) and 8 solid malignancy (0.45%). Median (min–max) SLEDAI-2 K scores were 9 (0–38), median (min–max) SLICC/ACR-DI (SDI) score were 1 (1–5) Histopathology defined 1 Hodgkin's lymphoma, 2 non-Hodgkin's lymphoma, 1 acute lymphoblastic leukaemia; 4 gastrointestinal carcinoma, 1 squamous cell carcinoma of the tongue and 1 anal carcinoma; 1 had sigmoid adenocarcinoma and 1 stomach carcinoid; 3 had genital malignancy, being 1 vulvae, 1 cervix and 1 vulvae and cervix carcinomas; 1 had central nervous system oligodendroglioma; and 1 testicle germ cell teratoma. Conclusion: Estimated malignancy frequency of 0.7% was reported during cSLE follow up in a multicentric series. Median disease activity and cumulative damage scores, by the time of malignancy diagnoses, were high; considering that reported in adult series.
- 6 February 2024
- Published by Springer Nature in Advances in Rheumatology
- Vol. 64 (1) , 1-7
Open AccessChildhood-onset systemic lupus erythematosus (cSLE) and malignancy: a nationwide multicentre series review
Background: Increased malignancy frequency is well documented in adult-systemic lupus erythematosus (SLE), but with limited reports in childhood-onset SLE (cSLE) series. We explored the frequency of malignancy associated with cSLE, describing clinical and demographic characteristics, disease activity and cumulative damage, by the time of malignancy diagnosis. Method: A retrospective case-notes review, in a nationwide cohort from 27 Pediatric Rheumatology centres, with descriptive biopsy-proven malignancy, disease activity/damage accrual, and immunosuppressive treatment were compiled in each participating centre, using a standard protocol. Results: Of the 1757 cSLE cases in the updated cohort, 12 (0.7%) developed malignancy with median time 10 years after cSLE diagnosis. There were 91% females, median age at cSLE diagnosis 12 years, median age at malignancy diagnosis 23 years. Of all diagnosed malignancies, 11 were single-site, and a single case with concomitant multiple sites; four had haematological (0.22%) and 8 solid malignancy (0.45%). Median (min–max) SLEDAI-2 K scores were 9 (0–38), median (min–max) SLICC/ACR-DI (SDI) score were 1 (1–5) Histopathology defined 1 Hodgkin's lymphoma, 2 non-Hodgkin's lymphoma, 1 acute lymphoblastic leukaemia; 4 gastrointestinal carcinoma, 1 squamous cell carcinoma of the tongue and 1 anal carcinoma; 1 had sigmoid adenocarcinoma and 1 stomach carcinoid; 3 had genital malignancy, being 1 vulvae, 1 cervix and 1 vulvae and cervix carcinomas; 1 had central nervous system oligodendroglioma; and 1 testicle germ cell teratoma. Conclusion: Estimated malignancy frequency of 0.7% was reported during cSLE follow up in a multicentric series. Median disease activity and cumulative damage scores, by the time of malignancy diagnoses, were high; considering that reported in adult series.
- Open Access
- 2 January 2024
- Published by Elsevier in Jornal de Pediatria
- Vol. 100 (3) , 311-317
Chronic neutropenia in childhood: experience of a tertiary center
- 2 January 2024
- Published by Elsevier in Jornal de Pediatria
- Vol. 100 (3) , 311-317
Open AccessChronic neutropenia in childhood: experience of a tertiary center
- 21 November 2022
- Published by Springer Nature in Pediatric Nephrology
- Vol. 38 (6) , 1843-1854
Chronic kidney disease in patients with childhood-onset systemic lupus erythematosus
Background Lupus nephritis (LN) is a frequent manifestation of childhood-onset systemic lupus erythematosus (cSLE) with a potential risk for kidney failure and poor outcomes. This study aimed to evaluate stages III, IV, and V of chronic kidney disease (CKD) and investigate risk factors for CKD in cSLE patients. Methods We performed a nationwide observational cohort study in 27 pediatric rheumatology centers, including medical charts of 1528 cSLE patients. Data were collected at cSLE diagnosis, during follow-up, and at last visit or death, between September 2016 and May 2019. Results Of 1077 patients with LN, 59 (5.4%) presented with CKD, 36/59 (61%) needed dialysis, and 7/59 (11.8%) were submitted for kidney transplantation. After Bonferroni’s correction for multiple comparisons (p < 0.0013), determinants associated with CKD were higher age at last visit, urinary biomarker abnormalities, neuropsychiatric involvement, higher scores of disease activity at last visit and damage index, and more frequent use of methylprednisolone, cyclosporine, cyclophosphamide, and rituximab. In the regression model analysis, arterial hypertension (HR = 15.42, 95% CI = 6.12–38.83, p ≤ 0.001) and biopsy-proven proliferative nephritis (HR = 2.83, 95%CI = 1.70–4.72, p ≤ 0.001) increased the risk of CKD, while children using antimalarials had 71.0% lower CKD risk ((1.00–0.29) × 100%) than children not using them. The Kaplan–Meier comparison showed lower survival in cSLE patients with biopsy-proven proliferative nephritis (p = 0.02) and CKD (p ≤ 0.001). Conclusions A small number of patients manifested CKD; however, frequencies of dialysis and kidney transplantation were relevant. This study reveals that patients with cSLE with hypertension, proliferative nephritis, and absence of use of antimalarials exhibited higher hazard rates of progression to CKD. Graphical Abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 21 November 2022
- Published by Springer Nature in Pediatric Nephrology
- Vol. 38 (6) , 1843-1854
Chronic kidney disease in patients with childhood-onset systemic lupus erythematosus
Background Lupus nephritis (LN) is a frequent manifestation of childhood-onset systemic lupus erythematosus (cSLE) with a potential risk for kidney failure and poor outcomes. This study aimed to evaluate stages III, IV, and V of chronic kidney disease (CKD) and investigate risk factors for CKD in cSLE patients. Methods We performed a nationwide observational cohort study in 27 pediatric rheumatology centers, including medical charts of 1528 cSLE patients. Data were collected at cSLE diagnosis, during follow-up, and at last visit or death, between September 2016 and May 2019. Results Of 1077 patients with LN, 59 (5.4%) presented with CKD, 36/59 (61%) needed dialysis, and 7/59 (11.8%) were submitted for kidney transplantation. After Bonferroni’s correction for multiple comparisons (p < 0.0013), determinants associated with CKD were higher age at last visit, urinary biomarker abnormalities, neuropsychiatric involvement, higher scores of disease activity at last visit and damage index, and more frequent use of methylprednisolone, cyclosporine, cyclophosphamide, and rituximab. In the regression model analysis, arterial hypertension (HR = 15.42, 95% CI = 6.12–38.83, p ≤ 0.001) and biopsy-proven proliferative nephritis (HR = 2.83, 95%CI = 1.70–4.72, p ≤ 0.001) increased the risk of CKD, while children using antimalarials had 71.0% lower CKD risk ((1.00–0.29) × 100%) than children not using them. The Kaplan–Meier comparison showed lower survival in cSLE patients with biopsy-proven proliferative nephritis (p = 0.02) and CKD (p ≤ 0.001). Conclusions A small number of patients manifested CKD; however, frequencies of dialysis and kidney transplantation were relevant. This study reveals that patients with cSLE with hypertension, proliferative nephritis, and absence of use of antimalarials exhibited higher hazard rates of progression to CKD. Graphical Abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 3 December 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (4) , e84-e86
Full-house nephropathy associated with high expression ofSPATA5L1due to a genetic pathogenic variant
Dear Editor, Non-lupus full-house nephropathy is a diagnostic challenge of yet unknown aetiology that does not satisfy criteria for SLE classification [ 1–3]. Spermatogenesis-associated protein 5-like protein 1 (SPATA5L1) is ubiquitously expressed in kidney and other tissues and has been previously associated with renal failure and chronic kidney disease (CKD) [ 4]. We describe a non-lupus full-house nephropathy case showing high SPATA5L1 protein expression in the kidney and other tissues due to a pathogenic missense genetic variant. The study was approved by the Clinical Hospital of the Ribeirão Preto Medical School Research Ethics Committee (process number 3.454.601/2019), and written informed consent was obtained from the parents. A 9-month-old Brazilian girl, born to non-consanguineous Brazilian parents, presented with nephrotic proteinuria a few days after an upper airway viral infection. After a conservative treatment approach, due to persistent proteinuria, the child received four consecutive days of methylprednisolone pulse and was kept with prednisolone PO and enalapril with no improvement. Screening for infectious diseases was negative ( Supplementary Table S1 , available at Rheumatology online). Renal biopsy evidenced membranous glomerulonephritis, class V for lupus nephritis [ 5]. Immunofluorescence revealed a ‘full-house’ pattern with intense, global, diffuse deposits of IgG, IgM and C1q in capillary loops and moderate mesangial deposits for C3 and IgA. Investigation for SLE was performed and no evidence of systemic autoimmunity was found. Autoantibodies were negative and remained negative during the 7-year follow-up period ( Supplementary Table S1 , available at Rheumatology online). After ruling out other causes of membranous nephritis, she was treated as non-lupus idiopathic full-house nephropathy. The patient had a poor treatment response to five monthly cyclophosphamide pulses and prednisolone, and when treatment was switched to azathioprine, she developed bone marrow (BM) failure, mainly of the megakaryocyte lineage. Due to persistent pancytopenia after azathioprine withdrawal, cyclosporine associated with methylprednisolone and intravenous immunoglobulin infusions was prescribed, and only after 40 days, signs of initial BM recovery were reached. Given the possibility of severe BM aplasia of immune aetiology, the patient received a standard treatment schedule for BM failure with antithymocyte globulin treatment.
- 3 December 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (4) , e84-e86
Full-house nephropathy associated with high expression ofSPATA5L1due to a genetic pathogenic variant
Dear Editor, Non-lupus full-house nephropathy is a diagnostic challenge of yet unknown aetiology that does not satisfy criteria for SLE classification [ 1–3]. Spermatogenesis-associated protein 5-like protein 1 (SPATA5L1) is ubiquitously expressed in kidney and other tissues and has been previously associated with renal failure and chronic kidney disease (CKD) [ 4]. We describe a non-lupus full-house nephropathy case showing high SPATA5L1 protein expression in the kidney and other tissues due to a pathogenic missense genetic variant. The study was approved by the Clinical Hospital of the Ribeirão Preto Medical School Research Ethics Committee (process number 3.454.601/2019), and written informed consent was obtained from the parents. A 9-month-old Brazilian girl, born to non-consanguineous Brazilian parents, presented with nephrotic proteinuria a few days after an upper airway viral infection. After a conservative treatment approach, due to persistent proteinuria, the child received four consecutive days of methylprednisolone pulse and was kept with prednisolone PO and enalapril with no improvement. Screening for infectious diseases was negative ( Supplementary Table S1 , available at Rheumatology online). Renal biopsy evidenced membranous glomerulonephritis, class V for lupus nephritis [ 5]. Immunofluorescence revealed a ‘full-house’ pattern with intense, global, diffuse deposits of IgG, IgM and C1q in capillary loops and moderate mesangial deposits for C3 and IgA. Investigation for SLE was performed and no evidence of systemic autoimmunity was found. Autoantibodies were negative and remained negative during the 7-year follow-up period ( Supplementary Table S1 , available at Rheumatology online). After ruling out other causes of membranous nephritis, she was treated as non-lupus idiopathic full-house nephropathy. The patient had a poor treatment response to five monthly cyclophosphamide pulses and prednisolone, and when treatment was switched to azathioprine, she developed bone marrow (BM) failure, mainly of the megakaryocyte lineage. Due to persistent pancytopenia after azathioprine withdrawal, cyclosporine associated with methylprednisolone and intravenous immunoglobulin infusions was prescribed, and only after 40 days, signs of initial BM recovery were reached. Given the possibility of severe BM aplasia of immune aetiology, the patient received a standard treatment schedule for BM failure with antithymocyte globulin treatment.
- Open Access
- 1 May 2021
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 25 (3) , 101585
Chronic arthritis related to SARS-CoV-2 infection in a pediatric patient: A case report
- 1 May 2021
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 25 (3) , 101585
Open AccessChronic arthritis related to SARS-CoV-2 infection in a pediatric patient: A case report
- Open Access
- 20 March 2021
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 19 (1) , 1-12
Disease activity index is associated with subclinical atherosclerosis in childhood-onset systemic lupus erythematosus
Background: Systemic lupus erythematosus (SLE) is an independent risk factor for cardiovascular events. The present study determined the prevalence of subclinical atherosclerosis in childhood-onset SLE using the carotid intima-media thickness (CIMT) measurement and investigated associations between traditional and nontraditional risk factors for atherosclerosis, such as medications, SLE Disease Activity Index - SLEDAI-2 K and SLICC-ACR damage index and CIMT. Methods: Cross-sectional prospective study between 2017 and 2018. CIMT was assessed by ultrasonography. Data were collected by chart review, nutritional evaluation and laboratory tests and analyzed by Fisher, Wilcoxon-Mann-Whitney tests, multiple linear and log binomial regression. Results: Twenty-eight patients (mean age 13.9 years, SD 3) were enrolled. The prevalence of subclinical atherosclerosis was 32% (95% CI 14.8, 49.4). The mean CIMT was 0.43 ± 0.035 mm. The most common traditional risk factors observed were dyslipidemia (82.1%), uncontrolled hypertension (14.2%), obesity (14.3%), and poor diet (78.6%). Uncontrolled hypertension (p = 0.04), proteinuria (p = 0.02), estimated glomerular filtration rate < 75 ml /min/1.73 m2 (p = 0.02) and SLEDAI-2 K > 5 (P = 0.04) were associated with subclinical atherosclerosis. SLEDAI-2 K > 5 maintained association with CIMT after adjusting for control variables. Conclusion: Subclinical atherosclerosis is frequently observed in cSLE, mainly in patients with moderate to severe disease activity.
- 20 March 2021
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 19 (1) , 1-12
Open AccessDisease activity index is associated with subclinical atherosclerosis in childhood-onset systemic lupus erythematosus
Background: Systemic lupus erythematosus (SLE) is an independent risk factor for cardiovascular events. The present study determined the prevalence of subclinical atherosclerosis in childhood-onset SLE using the carotid intima-media thickness (CIMT) measurement and investigated associations between traditional and nontraditional risk factors for atherosclerosis, such as medications, SLE Disease Activity Index - SLEDAI-2 K and SLICC-ACR damage index and CIMT. Methods: Cross-sectional prospective study between 2017 and 2018. CIMT was assessed by ultrasonography. Data were collected by chart review, nutritional evaluation and laboratory tests and analyzed by Fisher, Wilcoxon-Mann-Whitney tests, multiple linear and log binomial regression. Results: Twenty-eight patients (mean age 13.9 years, SD 3) were enrolled. The prevalence of subclinical atherosclerosis was 32% (95% CI 14.8, 49.4). The mean CIMT was 0.43 ± 0.035 mm. The most common traditional risk factors observed were dyslipidemia (82.1%), uncontrolled hypertension (14.2%), obesity (14.3%), and poor diet (78.6%). Uncontrolled hypertension (p = 0.04), proteinuria (p = 0.02), estimated glomerular filtration rate < 75 ml /min/1.73 m2 (p = 0.02) and SLEDAI-2 K > 5 (P = 0.04) were associated with subclinical atherosclerosis. SLEDAI-2 K > 5 maintained association with CIMT after adjusting for control variables. Conclusion: Subclinical atherosclerosis is frequently observed in cSLE, mainly in patients with moderate to severe disease activity.